Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midomafetamine PK/PD and Safety Study in Healthy Adults
NCT07584720Phase 1Active, not recruiting
- Sponsor
- Resilient Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Resilient Pharmaceuticals. Primary endpoint: Incidence of Adverse Events at Day 30. Started Apr 2026; status: active, not recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07584720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584720.